1. Introduction {#sec1}
===============

The cancer is a major non-communicable disease posing substantial social and economical challenges in both developing and developed countries. The rapid rise in cancer mortality rates accounting together for China, India and Russia is nearly twofold high compared to the UK and the USA. The number of factors contributed for rapid rise in cancer incidence in the growing economies include changes in lifestyles (food habit, decreased physical activity and sedentary lifestyles), low socio-income populations with minimum cancer care facility, different contaminants of the environment, increase in aged populations, and increase in oncogenic communicable infective organisms \[[@bib1], [@bib2]\]. According to International Agency for Research on Cancer GLOBOCAN project, the rise in the cancer burden in India will nearly be double in the next 20 years and is predicted to be more than 1.7 million cases by 2035 \[[@bib2],[@bib3]\].

In the current scenario, the options available for treatment of different cancer are associated with various limitations, including severe toxicity, drug resistance, poor outcomes and a high risk of relapse. Hence, an increased attention and necessity for screening of various phytochemicals from natural sources for superior and safer alternative has been ongoing for several decades. The chemo-preventive agents available from the different parts of plants are used in the form of alternative and evidence-based complementary system of medicine along with the current chemotherapy and/or radiation therapy [@bib4]. The recent research focus has shifted to the molecular mechanisms of these natural phytoconstituents on various signal transduction mechanisms controlling the cell growth and the cell cycle.

*Acorus calamus* (L.) (Sweet flag), a member of the family Acoraceae, generally used alone or in combination with other herbs in Indian and Chinese traditional medicine has generated great interest and is found to be beneficial [@bib5]. *Acorus gramineus* (S.) and *Acorus tatarinowii* (S.) (Acoraceae), the other plants from *Acorus* species are officially listed in the Chinese Pharmacopoeia \[[@bib6], [@bib7]\]. The plant is widely cultivated in different parts of temperate and sub-temperate regions of the world and is native to India, Sri Lanka, Japan, China, Burma, Mongolia, Southern Russia, Europe and Northern USA \[[@bib8], [@bib9]\]. The habitat of the herbaceous perennial plant *A. calamus*, is semi-aquatic and terrestrial with creeping rhizomes. The rhizomes are bitter in taste, highly branched, pinkish or pale green in color and citrus in odor \[[@bib8], [@bib10]\]. In this review, we have summarized and discussed the anti-cancer properties of *A. calamus* and/or its main bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) and related mechanisms based on *in-vitro* and *in-vivo* experimental evidences.

1.1. Chemical constituents of *Acorus calamus* {#sec1.1}
----------------------------------------------

In general, *A. calamus* consists of various phytoconstituents namely glycosides (xanthone), volatile oil, sesquiterpenes, monoterpenes, flavonoids, steroids, saponins, lignin, tannins, mucilage, alkaloid and polyphenolic compounds \[[@bib11], [@bib12]\]. The two main bioactive aromatic constituents isolated from the rhizomes of *A. calamus* are alpha (α)-asarone (1,2,4-trimethoxy-5-\[(E)-prop-1-enyl\] benzene) and beta (β)-asarone (1, 2, 4-trimethoxy-5-\[(Z)-prop-1-enyl\] benzene). Beside these, it also contains the other essential oil such as calamenol, calameon and calamen. The chemical structures of the various constituents of *A. calamus* are illustrated in [Fig. 1](#fig1){ref-type="fig"} \[[@bib5],[@bib13],[@bib14]\].Fig. 1Chemical structures of various constituents obtained from *A. calamus*.Fig. 1

1.2. Ethnomedicinal and pharmacological properties of *Acorus calamus* {#sec1.2}
----------------------------------------------------------------------

The traditional use of *Acorus calamus* in Indian Ayurvedic system is widely accepted. The plant has been used to cure several diseases like asthma, fever, cough, epilepsy, hysteria, skin diseases, depression, haemorrhoids, diarrhea, insomnia, dysentery, kidney and liver problems, mental retardation, bronchitis and as a sedative. The external application of the paste of *A. calamus* on rheumatism, inflamed joints and rheumatic fever improves the pain and swelling in people. The natives of Alberta use *A. calamus* for prevention of headache, toothache, hangover and as a disinfectant for teeth. Further, in Western herbal medicine, the plant is mainly employed for gastrointestinal related problems like bloating, gas, colic and poor digestive function. In China, it is used by ethnic groups to cure constipation, digestive problems and for decreasing swelling. The plant is also found to reduce the stress-induced suppression of immunity and improves the immunity in experimental rats. The pharmacological studies have established numerous beneficial properties including anti-oxidant, anti-inflammatory, anti-cancer, anti-ulcer, anti-fungal, anti-allergic, anti-diabetic, anti-microbial, wound healing, neuroprotective, radioprotective, pesticidal, insecticidal and cardioprotective effects and others which are depicted in [Fig. 2](#fig2){ref-type="fig"}. The plant had a long antiquity and numerous ethnomedicinal, pharmacological and economic applications. Several medicinal practices allow to surpass diverse cultural barriers thereby gaining its widespread usage. Henceforth, considering and incorporating both ecological and socio-economic aspects is important when the demand of the products increased with respect to trade commodities and distant market \[[@bib10], [@bib11], [@bib15], [@bib16], [@bib17], [@bib18]\].Fig. 2Schematic representation of various pharmacological activity of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).Fig. 2

The recent publications indicate the growing interest in the potential of *A. calamus* and its main constituents as chemo preventive agent/s ([Fig. 3](#fig3){ref-type="fig"}). Various experimental investigations of *A. calamus* and its main constituents with cultured human malignant cell lines and animal models have confirmed antitumor and cancer preventive activities. The subsequent section provides a brief understanding into the anticancer properties of *A. calamus* and/or its bioactive phytochemicals (α)- and (β)-asarone.Fig. 3Number of publications per year on *A. calamus* and/or its bioactive phytochemicals asarones. The PubMed database (<https://www.ncbi.nlm.nih.gov/pubmed/>) was searched with the keywords "*Acorus calamus* and cancer" and "asarone and cancer".Fig. 3

2. Main text {#sec2}
============

2.1. *In-vitro* anti-cancer properties of *A. calamus* or asarone {#sec2.1}
-----------------------------------------------------------------

### 2.1.1. Effect of (β)-asarone in human glioblastoma U251 cells {#sec2.1.1}

The most common type of primary malignant brain tumor accounts for 82 % cases of malignant gliomas. Glioblastoma is characterized by rapid growth, enhanced angiogenesis and capacity for higher invasion. Although, the current combination therapy has doubled the survival rate in patients with glioblastoma but it remains enormously poor due to severe toxicity, drug resistance and high rates of recurrence \[[@bib19], [@bib20]\]. Qi *et al.* studied the cytotoxic effect of (β)-asarone in human glioblastoma U251 cells. They studied the cell death by fluorescent staining using YO-PRO-1 and propidium iodide (PI), which revealed that the cells treated by (β)-asarone underwent apoptotic and necrotic death. A proteomic based strategy was carried out to characterize the U251 cells treated with or without (β)-asarone to clarify the differential protein targets. In total, seven up-regulated and nine down-regulated proteins were identified by matrix assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF) mass spectrometer. The identified proteins were analyzed by gene ontology (GO) based on cellular components, molecular function and biological processes. Among them, four important proteins namely heterogeneous nuclear ribonucleoprotein H1 (H), isoform CRA_b (hnRNP H1isoform CRA b), heterogeneous nuclear ribonucleo-protein A2/B1, isoform CRA a (hnRNP A2/B1 isoform CRA a), ubiquitin carboxyl-terminal hydrolase isozyme L1 and cathepsin D) were identified to potentially serve as the therapeutic targets. Finally, the changes in the protein alterations were correlated with the mRNA at the transcriptional level by semi-quantitative RT-PCR technique. These results indicated that hnRNP H1 may be involved in HER-2/neu-driven tumor proliferation, invasion and metastasis. Further, authors suggested that the hnRNP A2/B1 could be used as a biomarker for prediction of glioma progression and can act as a novel oncogene in glioblastoma. They concluded that (β)-asarone is effective as anti-tumor agent as it was shown to inhibit the expression of hnRNP H1, hnRNPA2/B1 and cathepsin D against brain tumor [@bib21].

In another study carried by Li *et al.*, the effect and mechanisms of (β)-asarone against tumor invasion and epithelial--mesenchymal transition (EMT) were explored. The inhibitory effects of (β)-asarone on the migration of U251 cells (wound healing assay), suppression of the invasion of U251 cells (Boyden chamber invasion assay) and inhibition of the adhesion of U251 cells (Matrigel) was evaluated. Further the down-regulation of hnRNP A2/B1 oncogenic protein by (β)-asarone supports the study done by Qi *et al.* In conclusion, the results suggested that (β)-asarone inhibits invasion and EMT in human glioma U251 cells by suppressing splicing factor hnRNP A2/B1 [@bib22]. The above study was further explored by Li *et al.* for the potential role of hnRNP A2/B1-mediated signaling pathway in the anti-glioma effect of (β)-asarone. They assessed the inhibitory effect of (β)-asarone on the cell viability of human glioma U251 cells by sulforhodamine B (SRB) assay and found it to be effective in a concentration and time dependent manner. Furthermore, the cell apoptosis was characterized with Annexin V/Pi staining by flow cytometry, where (β)-asarone induces cell apoptosis rate and cell cycle arrest at the G~1~ phase through modulation of p21, p27, cyclin D, cyclin E, CDK2 and Cdc25A. They also demonstrated that the ratio of Bcl-xS/Bcl-xL was enhanced by (β)-asarone in both mRNA and protein level by the inhibition of hnRNP A2/B1-mediated signaling pathway [@bib23]. The P-glycoprotein (P-gp) is a major cause of tumors resistance to chemotherapeutic agents. The relationship between cell resistance and P-gp is crucial as many tumors overexpresses the P-gp gene multi drug resistance-1 (MDR1). Wang *et al.* suggested that (β)-asarone might contribute to the treatment by promoting Temozolomide\'s (TMZ) entry into the glioma cells and can inhibit the expression of P-gp and MDR1 mRNA better than single TMZ. This data was further supported by examining the expression of P-gp with different methods and all of the results showed that the expression of P-gp and MDR1 mRNA level decreased in the (β)-asarone, TMZ and co-administration groups, whereas the co-administration group showed better effect [@bib24]. The above study was further continued by Wang *et al*, focusing on the effect of (β)-asarone induced cell death in U251 cells. They concluded that (β)-asarone can inhibit the progression of glioma U251 cells by arresting the cell cycle in G~0~/G~1~ phase and promoting autophagy possibly through P53/Bcl-2/Belin-1 and P53/AMPK/mTOR signal transduction pathway [@bib25] ([Table 1](#tbl1){ref-type="table"}; Figs. [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6](#fig6){ref-type="fig"}).Table 1*In-vitro* effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) on human cancer cell lines.Table 1Cell linesTreatmentTargets/Possible molecular eventsReferenceGlioblastoma (U251 cells)(β)-asarone\
(240 and 360 μM)Apoptosis (YO-PRO-1 and PI staining).\
Inhibition of the expression of hnRNP H1, hnRNPA2/B1 and cathepsin D.[@bib21]Glioblastoma (U251 cells)(β)-asarone\
(30 and 60 μM)Inhibition of the migration (Wound healing assay).\
Suppression of the invasion (Boyden chamber invasion assay).\
Inhibition of adhesion (Matrigel coated).\
↓ epithelial--mesenchymal transition (EMT) via upregulation of E-cadherin and down-regulation of vimentin.\
Inhibition of the expression of hnRNP A2/B1 in a concentration and time-dependent way.\
↓ expression of matrix metalloproteinases (MMP-9) and p-STAT3.[@bib22]Glioblastoma (U251 cells)(β)-asarone\
(60, 120, 240 and 480 μM)Apoptosis (Annexin V/Pi staining).\
Cell cycle arrest at G~1~ phase.\
Inhibition of the expression of hnRNP A2/B1 in a concentration and time-dependent way.\
Ratio of Bcl-xS/Bcl-xL ↑ by (β)-asarone in both mRNA and protein level by the inhibition of hnRNP A2/B1-mediated signaling pathway.\
Promoted the activation of the death receptor proteins TRAIL and FasL.\
Cleavage of caspase 8 and caspase 3.\
↑ in the expression of cleaved-BID and cellular protein cytochrome C.\
↑ in the expression of cell cycle related proteins p21 and p27 and ↓ in expression of cyclin D, cyclin E, Cdc25A and CDK2.[@bib23]Glioblastoma (U251 cells)(β)-asarone\
(360 μM)↓ in the cell proliferation in the medicated groups (CCK-8 assay).\
↓ in the expression of P-glycoprotein (P-gp) in the medicated groups.\
↓ in the expression of multi drug resistance-1 (MDR1) mRNA expression.[@bib24]Glioblastoma (U251 cells)(β)-asarone\
(360 μM)↓ in the cell proliferation in the medicated groups (CCK-8 assay).\
Cell cycle arrest at G~0~/G~1~ phase.\
Formation of autophagosome (double-membrane autophagosomes and single-membrane autolysosomes) was observed.\
↑ in the expression of autophagic markers like Beclin-1 and LC3-Ⅱ/Ⅰ and ↓ in the expression of p62.\
↑ in the expression of P53 mRNA, P53, AMPK and pAMPK and ↓ in the expression of Bcl2, mTOR and pmTOR.[@bib25]Colon cancer (LoVo cells)(β)-asarone\
(200 and 400 μM)↓ in the rate of cell viability (MTT assay).\
Ultra-structure changes of the LoVo cells indicating apoptosis (Hoechst staining).\
Apoptosis (Annexin V-FITC/PI staining).\
Down-regulation of mitochondrial membrane potential (MMP).\
↑ proapoptotic proteins (Bax expression) and ↓antiapoptotic regulators (Bcl-2, Bcl-xL and survivin)\
↓ in the Bcl-2/Bax ratio and ↑ of the executer apoptosis enzyme caspase-9 and caspase-3 cascades.[@bib27]Colorectal cancer (HT29 and SW480 cells)(β)-asarone\
(0, 10, 30 and 100 nM)↓ in the cell proliferation (MTT assay).\
Induces cell senescence (SA- β -Gal activity).\
↑ in the levels of lamin B1, as well as p53, p21 and p15.[@bib28]Colon adenocarcinoma (Caco-2 cells)(α)- and (β)-asarone\
(30 μg/ml)Enhancement of the vincristine induced cytotoxicity to cells (MTT assay).\
↑ in the intracellular accumulation of Rhodamine 123 (Rh123) uptake and inhibited Rh123 efflux in Caco-2 cells.\
↓ expression of multi drug resistance-1 (MDR1) gene and P-glycoprotein (P-gp).[@bib29]Gastric cancer (SGC-7901, BGC-823 and MKN-28 cells)(β)-asarone\
(0.12 and 0.24 mM)↓ in the cell viability (MTT assay).\
Apoptosis (Annexin V-FITC/PI staining).\
Ultra-structure changes of the cells indicating apoptosis (Hoechst 33342 staining).\
Inhibited the migration, invasion and adhesion (Wound-healing, transwell and matrix-cell adhesion assay).\
Activates caspase-3, 8 and 9 levels.\
↑ proapoptotic proteins (Bax and Bak expression) and ↓ antiapoptotic regulators (Bcl-2, Bcl-xL and surviving activity).\
↑ in the expression of RECK, E-cadherin and ↓ the expression of MMP-2, MMP-9, MMP-14 and N-cadherin.[@bib30]Gastric adenocarcinoma (AGS cells)Alcoholic extracts of *A. calamus* (15, 30, 60, 120, 240 and 480 μg/ml)Anti-proliferative effects (MTT assay).\
Cell cycle arrest at G~1~ phase.\
Inhibition of formation of tube-like structures confirming anti-angiogenic property (Tube formation assay).\
Down-regulation of Oct4 and Nucleostemin.[@bib31]Fibroblast (HSkMC cells)Prostate cancer (LNCaP cells)Ethanolic extract of *A. calamus* (250, 500 and 750 μg/ml)↓ in the cell viability (XTT assay).\
Induces apoptotic cell death (↑ in cleaved poly (ADP-ribose) polymerase/PARP).\
↓ in VEGF mRNA expression.[@bib33]Prostate cancer (PC-3 cells)Nitro derivatives of (β)-asarone\
(1.56--200) μM↓ in the cell viability (MTT assay).[@bib34]Neuroblastoma (IMR-32 cells)Cervical cancer (HeLa cells)Synovial cancer (SW982 cells)Breast cancer (MCF-7 cells)Macrophage cancer (P338D1 and J774 cells)Novel lectins from *Acorus* species (1.0--10) μg/ml↓ in the cell viability (^3^H-thymidine incorporation).[@bib35]T cell lymphoma (A20 cells)B cell lymphoma (WEHI-279 cells)Cervical cancer (HeLa cells)Green silver nanoparticles synthesized from *A. calamus* (25, 50, 75, 100, 125, 150, 175 and 200 μg/ml)Anti-proliferative effect (% inhibition of cell proliferation through MTT assay).\
Apoptotic cell death (Acridine orange/ethidium bromide (AO/EB) and annexinV-Cy3 staining and TUNEL assay).\
Nuclear changes as fragmentation and condensation (propidium iodide (PI) and 4′, 6-diamidino-2-phenylindole dilactate (DAPI) staining).[@bib36]Adenocarcinoma (A549 cells)Breast carcinoma (MDA-MB-435S cells)Aqueous and methanolic extracts of *A. calamus* (15.625, 31.25,62.5 and 125 μg/ml)↓ in the percentage mitotic index of root tip cells and cell viability (*Allium cepa* root tip and XTT assay).[@bib41]Liver carcinoma (Hep3B cells)[^1]Fig. 4The possible site of action of beta (β) asarone in apoptosis, cell proliferation and growth. (A) The (β)-asarone regulates the levels of the key proteins involved in the cell death and mitochondrial apoptosis pathway. (β)-asarone results in enhancement of the ratio of Bcl-xS/Bcl-xL via inhibition of hnRNP A2/B1-mediated signaling pathway, which may be correlated with (β)-asarone-induced apoptosis. On the other hand, the increased expression of cleaved-caspase 3, 8 and 9 along with the activation of the death receptor proteins TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL), it results in the induction of apoptosis. (B) (β)-asarone induced the cell cycle arrest at G~0~/G~1~ phase through the up-regulation of cell cycle related proteins as p21 and p27 and down-regulation of cyclin D, cyclin E, Cdc25A and CDK2. \[Possible site of action of (β)-asarone as observed in glioblastoma (U251 cells), colon cancer (LoVo cells), colorectal cancer (HT29 and SW480 cells), gastric cancer (SGC-7901, BGC-823 and MKN-28 cells), gastric adenocarcinoma (AGS cells), fibroblast (HSkMC cells) and prostate cancer (LNCaP cells)\].Fig. 4Fig. 5The possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) in tumor cell metastasis, invasion, migration and angiogenesis. (A) The (β)-asarone decreases the expression of epithelial-mesenchymal transition (EMT) through upregulation of E-cadherin and down-regulation of vimentin or N-cadherin via inhibition of the expression of hnRNP A2/B1-mediated signaling pathway, thereby suggesting (β)-asarone may block the process of EMT process in cancerous cells. (B) Matrix metalloproteinases (MMPs) are involved in the hnRNP A2/B1-related cancer invasion, migration and metastasis. *A. calamus* and/or asarone suppresses the expression of matrix metalloproteinases (MMP-2, 9 and 14) and vascular endothelial growth factor (VEGF) thereby underlying the inhibitory effect on invasion, migration and metastasis. \[Possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) as observed in glioblastoma (U251 cells), colon cancer (LoVo cells), gastric cancer (SGC-7901, BGC-823 and MKN-28 cells) and prostate cancer (LNCaP cells)\].Fig. 5Fig. 6The possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) in cellular senescence and autophagy. It inhibits carcinogenesis by inducing cellular senescence through activation of lamin B1. Elevated lamin B1 promotes p53 and p21 expression, and recruits Oct-1 or 4 onto nuclear envelope and prevents binding to the p15 promoter, upregulating p15. On the other hand, activated p53 inhibits Bcl-2, which induces cell apoptosis in the cell cycle. Further autophagy is promoted through up-regulation of autophagy related proteins (Beclin-1 and LC3-II/I) and down-regulation of p53 related proteins (mTOR, Bcl-2). Atg: Autophagy related gene; mTOR: Mammalian target of rapamycin; Oct-1/4: Octamer-binding protein-1,4; LC3: Microtubule-associated proteins 1A/1B light chain 3B. \[Possible site of action of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone) as observed in glioblastoma (U251 cells), colorectal cancer (HT29 and SW480 cells), fibroblast (HSkMC cells) and gastric adenocarcinoma (AGS cells)\].Fig. 6

### 2.1.2. Effect of (β)-asarone in human colorectal cancer {#sec2.1.2}

The incidence of the colorectal cancer (CRC) is the third most common type of cancer and a leading cause of cancer-related mortality in developed and developing countries [@bib26]. The effectiveness of chemotherapeutic agents is often limited due to high occurrence of severe side effects and drug resistance. Hence, search for new treatment strategies for CRC is ongoing since several decades. In a study undertaken by Zou *et al.*, the anticancer properties by upregulation of caspases activity through the mitochondrial pathway in human colon cancer cells was determined. The (β)-asarone showed dose- and time-dependent cell viability in human LoVo colon cancer cells and induced cell apoptosis by annexin V, which was estimated by fluorescein isothiocyanate/propidium iodide assay by flow cytometry. Further, the relative mRNA expression levels of pro-and anti-apoptotic factors were determined particularly focusing on the change of mitochondrial membrane potential (MMP) via activation of caspase-9, caspase-3 and the ratios of Bcl-2/Bax and Bcl-xL/Bax [@bib27]. The suppression of cellular senescence is one of the features of colorectal cancer and has been linked with aging. One of the factors involved in cellular senescence is the lamin proteins. The lamin B1 gene is suppressed in primary human and murine cell lines when they endure senescence after DNA damage. In another study Liu *et al.* establish that the (β)-asarone effectively targets cell senescence via lamin protein leading to cell survival. Human colorectal cell lines HT29 and SW480 were treated with (β)-asarone and it had a time- and dose-dependent effect on cell viability. Finally, authors concluded that (β)-asarone inhibits colorectal carcinogenesis by inducing cellular senescence through lamin B1 gene. The increased lamin B1 promotes p53 and p21 expression, and recruits Oct-1 onto nuclear envelope and prevents binding to the p15 promoter, upregulating p15 [@bib28]. Beside that, multiple drug resistance (MDR) is one of the major barriers in cancer chemotherapy. Meng *et al.* reported that both (α)- and (β)-asarone significantly enhanced the vincristine induced cytotoxicity in human colon adenocarcinoma (Caco-2) cells by enhancing the influx and inhibiting a transmembrane efflux pump (P-Glycoprotein) functions in a concentration dependent manner. Further, it was found that the (α)- and (β)-asarone cause the reduction in P-gp expression and P-gp mRNA in cells [@bib29] ([Table 1](#tbl1){ref-type="table"}; Figs. [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6](#fig6){ref-type="fig"}).

### 2.1.3. Effect of (β)-asarone/alcoholic extracts of A. calamus in human gastric cancer cells {#sec2.1.3}

Gastric or stomach cancer is the fourth most common gastrointestinal malignancy. The primary therapy, surgery combined with chemotherapy may achieve satisfactory results, but is not useful for advanced stage of gastric cancer. A study was undertaken by Wu *et al.* to explore the impact of (β)-asarone on human gastric cancer cells along with establishment of the possible mechanism. The effect of (β)-asarone was studied on three types of differentiated human gastric cancer cell lines such as SGC-7901, BGC-823 and MKN-28. The (β)-asarone inhibits the proliferation of gastric cancer cells in a dose-dependent manner and induces early apoptosis. Further, transwell and wound-healing assays reveals that (β)-asarone inhibited the migration of BGC-823 cells in a concentration-dependent manner. Finally, mRNA and protein expression changes for studying the mechanism of action on the apoptosis of gastric cancer cells was carried out with western blotting and RT-PCR technique. This study clearly depicts that (β)-asarone inhibited the gastric cancer cell growth by upregulating the expression of caspases, proapoptotic proteins, RECK, E-cadherin and by downregulating the expression of antiapoptotic proteins, matrix metalloproteinases and N-cadherin [@bib30]. Haghighi *et al.* investigated the anti-cancer and anti-angiogenic activity of the alcoholic extracts and essential oil of *A. calamus* on gastric cancer cell line (AGS) and compared with primary human fibroblast cell line (HSkMC). The growth inhibitory effects of the extracts and essential oil have a concentration and time dependent significant reduction in the proliferation of AGS cells and cell cycle arrest at G~1~ phase. Further, the tube formation assay showed anti-angiogenic effects of the extracts and essential oil. It was finally supported by the downregulation of Oct4 and Nucleostemin after treatment of the cells with the extracts as confirmed by flowcytometry and quantitative RT-PCR [@bib31] ([Table 1](#tbl1){ref-type="table"}; Figs. [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, and [6](#fig6){ref-type="fig"}).

### 2.1.4. Effect of (β)-asarone/ethanolic extracts of A. calamus in human prostate cancer cells {#sec2.1.4}

Prostate cancer is the most commonly diagnosed cancer and remains the third-leading cause of cancer death in men [@bib32]. The pro-angiogenic factor - vascular endothelial growth factor-A (VEGF-A) is believed to be the single most significant angiogenic factor in prostate cancer for accelerating all stages of angiogenesis making it a desirable target. A recent study suggested that the ethanolic extract of *A. calamus* root possesses a dose and time dependent anticancer, apoptotic and anti-angiogenic activities on prostate cancer cell culture. Koca *et al.* examined whether ethanolic extract of *A. calamus* marks the survival and apoptosis as well as inhibits the angiogenesis. The effect of *A. calamus* extract on the cell viability showed a dose-response relationship of cell survival. The Poly-(ADP-ribose) polymerase (PARP) cleavage involved in the apoptotic process was found to be at higher expression in *A. calamus* extract treated cells. It was also supported by the suppression of mRNA expression of the pro-angiogenic factor VEGF-A in LNCaP cells treated with the *A. calamus* extract [@bib33]. Shenvi *et al.* reported the anti-cancer assay of nitro derivatives of (β)-asarone using PC-3 (prostate cancer) cell line along with four other different types of human cancer cell lines by using MTT assay. The nitration derivative compounds of (β)-asarone exhibited an increase in activity compared to (β)-asarone confirming its cytotoxic activity in all the cell lines [@bib34] ([Table 1](#tbl1){ref-type="table"}; Figs. [4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

### 2.1.5. Effect of novel lectins from *Acorus* species in murine cancer cells {#sec2.1.5}

Lectins, the major proteins of many monocotyledonous plants are polyclonal activators towards human lymphocytes. In a study performed by Bains *et al*, they reported two novel lectins derived from the rhizomes of *A. calamus* and *A. gramineus* possessing significant mitogenic activity towards human lymphocytes and inhibitory activity towards murine macrophage cancer cell lines. They employed macrophage cancer cell lines (P338D1 and J774), T cell lymphoma (A20) and B cell lymphoma (WEHI-279) for MTT assay to study the inhibitory activity of the novel lectins. Both the novel lectins (*A. calamus* and *A. gramineus*) showed inhibitory activity towards the murine cancer cell lines as measured by ^3^H-thymidine incorporation confirming its inhibitory potential [@bib35] ([Table 1](#tbl1){ref-type="table"}).

### 2.1.6. Effect of green silver nanoparticles synthesized from A. calamus rhizome extract in human cervical cancer (HeLa) and lung adenocarcinoma (A549) cell lines {#sec2.1.6}

The use of the inert metals such as gold, silver, and platinum in the field of nanomedicine is gaining interest for synthesizing metallic nanoparticles having high therapeutic potential for various uses. Green synthesis of silver nanoparticles using various medicinal plants have shown to exhibit *in-vitro* anticancer activities. Keeping view of the above evidences, Nakkala *et al.* carried out the *in-vitro* cytotoxic effects of green silver nanoparticles synthesized from *A. calamus* rhizome extract (ACAgNPs) in human cervical cancer (HeLa) and lung adenocarcinoma (A549) cell lines. The anti-proliferative effect expressed as % inhibition of cell proliferation through MTT assay were found within the acceptable concentration of 100 mg/L. The apoptotic cell death was confirmed further through acridine orange/ethidium bromide (AO/EB) and annexinV-Cy3 staining techniques being supported by the nuclear changes (fragmentation and condensation) through staining with propidium iodide (PI) and 4′, 6-diamidino-2-phenylindole dilactate (DAPI) and flow cytometry. Collectively, all these findings suggested the cytotoxic activity of green silver nanoparticles synthesized with *A. calamus* rhizome extract [@bib36] ([Table 1](#tbl1){ref-type="table"}).

2.2. *In-vivo* anti-cancer effect of *A. calamus* {#sec2.2}
-------------------------------------------------

Beside *in-vitro* investigation, *in-vivo* studies provided the evidence supporting that *A. calamus* and/or its bioactive phytochemicals asarone have potential anti-cancer pharmacological effect. Here, we discussed the detailed evidence about the anti-cancer effect of *A. calamus* and/or its bioactive phytochemicals asarone.

Zou *et al.* evaluated the anti-cancer property of (β)-asarone in nude mice through LoVo cancer xenografts model. The experimental animals treated with (β)-asarone at 50 mg/kg/d b.w. concentration suppressed the tumor volume significantly in comparison to placebo controls. Further, to determine that the tumors in the (β)-asarone treated group were inhibited through apoptosis, the isolated tumors was subjected to TUNEL assay. It was confirmed that fragmentation of DNA was observed in the growth-inhibited tumors for the nude mice suggesting the apoptotic changes [@bib27]. Furthermore, another study carried by Liu *et al.* revealed that (β)-asarone treatment reduced the incidence and number of tumor formation against the genotoxic colonic chemical carcinogen DMH (1, 2-dimethyl hydrazine) in Crj: CD-1 (ICR) mice. Moreover, the reduction in the tumor volume in xenografts model of colorectal cancer in BABL/c nude mice through administration of SW480 or HT-29 cells was observed in the (β)-asarone treated group. It was further supported by data that (β)-asarone induced senescence in human colorectal cancer via activation of lamin B1 by promoting the tumor protein (p53, p21) expressions [@bib28]. Our earlier study reported that (β)-asarone treatment protects the rats from the diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) which was confirmed by the changes in the levels of the liver function markers and cancer bio-marker (alpha-fetoprotein) and supported by histopathological changes [@bib37]. Recently, it was reported that (β)-asarone inhibits tumor growth and induces apoptosis in U251 tumor xenograft nude mice model. The tumor was harvested for apoptosis with a standard *in-situ* terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and found that the apoptotic rate in the tumors significantly enhanced in (β)-asarone treatment group when compared with that of vehicle control. Furthermore, the expression of apoptotic proteins in tumor tissues was observed by the increase level of cleaved caspase-3 in the treated group. A dose-dependent decrease of the expression of hnRNP A2/B1 and CKD2, increase ratio of Bcl-xS/Bcl-xL and along with that increase expression of p27 was observed for the treated group when compared with that of the vehicle group. Finally, the results obtained in this study demonstrates that (β)-asarone -induced apoptosis and cell cycle arrest of U251 cells may be linked to the suppression of hnRNPA2/B1-mediated signaling pathway [@bib23] ([Table 2](#tbl2){ref-type="table"}).Table 2*In-vivo* anti-cancer effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).Table 2Model/Animal usedTreatmentTargets/Effects/Possible molecular eventsReferenceLoVo cancer xenograft model (Nude mice)(β)-asarone\
(50 mg/kg/d b.w.; *p.o.*)Suppression of the tumor volume.\
Apoptosis as confirmed by fragmentation of DNA in the growth-inhibited tumors (TUNEL assay).[@bib27]DMH (1, 2-dimethyl hydrazine) induced colorectal cancer\
(Crj: CD-1 (ICR) mice)(β)-asarone\
(50, 100 and 200 μg/kg/d b.w.; *p.o.*)Reduction in the incidence and number of tumor formation.\
Induction of senescence in human colorectal cancer via activation of lamin B1 by promoting the tumor protein (p53, p21) expressions.[@bib28]Human colorectal cancer (SW480 and HT-29 xenograft model) (BABL/c nude mice)(β)-asarone\
(50, 100 and 200 μg/kg/d b.w.; *i.v.*)Diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) (wistar Albino rats)(β)-asarone\
(25 μg/kg/d b.w.; *p.o.*)↓ in the levels of serum liver biomarkers (ALT, AST, ALP, TB and DB).\
↓ in the levels of cancer biomarkers (DNA, RNA and AFP).[@bib37]Glioma U251 tumor xenograft model (Nude mice)(β)-asarone\
(25 and 50 mg/kg/d b.w.; *p.o.*)Suppression of the tumor growth.\
↑ in the apoptotic rate (TUNEL assay).\
↑ level of apoptotic proteins (cleaved caspase-3 and p27).\
↓ in the expression of hnRNP A2/B1 and CKD2.\
↑ in ratio of Bcl-xS/Bcl-xL.[@bib23]Dalton\'s ascites lymphoma induced tumor (swiss Albino mice)Methanolic extracts of *A. calamus* (100 and 200 mg/kg/d b.w.; *i.p.)*↑ in the liver antioxidant enzyme level of SOD, CAT, GPx, GSH, Vitamin C and E.\
↑ in the kidney antioxidant enzyme level of SOD, CAT, GPx, GSH, LPO and Vitamin E.\
↓ in the tumor volume.\
↓ in the levels of serum liver biomarkers (ALT, AST and ALP).\[[@bib42], [@bib43], [@bib44]\][^2]

2.3. Anti-oxidant properties of *A. calamus* or asarone {#sec2.3}
-------------------------------------------------------

Anti-oxidants are known free radical scavengers that allow the cells to rejuvenate from cellular damage by neutralizing the highly reactive oxygen compounds [@bib38]. The anti-oxidant effect of *A. calamus* or asarone was reported by different *in-vitro* and *in-vivo* studies ([Table 3](#tbl3){ref-type="table"}). The bioactive compounds of the plant showed up/down regulation of certain endogenous enzymatic and non-enzymatic parameters which ultimately proves their ability to scavenge free radicals. Various reports suggest that the *A. calamus* or asarone are effective against number of oxidative stress models viz., ischemia-induced brain infarction oxidative stress, γ-radiation induced alterations in oxidative stress, noise stress-induced oxidative stress in brain etc.Table 3*In-vitro* and *in-vivo* anti-oxidant effect of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).Table 3Model/Animal used/Cell linesTreatmentTargets/Effects/Possible molecular eventsReference*In-vitro* anti-oxidant activityEssential oils of *A. calamus* (5--25) μL/mLThe oils isolated from the rhizome and leaves in all the different seasons exhibited antioxidant activity as confirmed by 2, 2-diphenyl picryl hydrazyl (DPPH), reducing power (RP) and chelating properties of Fe^2+^.[@bib45]*In-vitro* anti-oxidant and free radical scavenging activityAqueous extracts of *A. calamus* (25--400) μg/mLResults showed that the aqueous extracts have a potential free radical scavenging activity as confirmed by DPPH, nitric oxide, superoxide radical, ferrous chelation, RP and phosphomolybdenum assay.[@bib46]*In-vitro* anti-oxidant activity(α)-asarone\
(10--100) μg/mLIt exhibited a dose-dependent DPPH radical-scavenging, RP, superoxide radical and hydroxyl radical scavenging activity.[@bib47]Ischemia-induced brain infarction oxidative stress (wistar rats)(β)-asarone\
(10, 20 and 30 mg/kg/d b.w.; *p.o.*)↑ in the levels of reduced glutathione (GSH), glutathione peroxidase (GPx), glutathione reductase (GR), glutathione S transferase (GST) and catalase (CAT) activity in the hippocampus.\
↓ in the level of lipid peroxidation (LPO) content in the hippocampus.[@bib48]Senescence- accelerated prone 8 (SAMP-8) (Alzheimer\'s mediated oxidative stress) (mice)(β)-asarone\
(34 mg/kg/d b.w.; *p.o.*)(β)-asarone did not affect superoxide dismutase (SOD) activities in brain and malondialdehyde (MDA) level in serum.[@bib49]High-fat diet (HFD) induced metabolic abnormalities oxidative stress (wistar rats)(β)-asarone\
(12.5, 25, and 50 mg/kg/d b.w.; *p.o.*)↑ levels of GSH and ↓ levels of MDA in liver homogenate.[@bib50]Noise stress-induced oxidative stress in brain (wistar rats)(α)-asarone\
(3, 6, and 9 mg/kg/d b.w.; *i.p.*)↓ in the levels of SOD and LPO content in the brain.\
↑ in the levels of CAT, GPx, GSH, Vitamin C, E and protein thiols in the brain.[@bib51]Brain enzymatic antioxidant activities (Swiss OF1 mice)(α)-asarone\
(100 mg/kg/d b.w.; *i.p.*)↑ in the levels of GPx and GR in the three areas of brain (cortex, striatum and hippocampus).\
SOD activity was unaffected in cortex and ↑ in striatum and hippocampus.[@bib52]γ-radiation induced alterations in oxidative stress (swiss Albino mice)(α)-asarone\
(50 mg/kg/d b.w.; *p.o.*)↑ in the levels of GSH, SOD, GPx and CAT in brain and kidney homogenate.[@bib53]Scopolamine induced cognitive deficits mediated oxidative stress (ICR mice)(α)-asarone\
(3, 10 and 30 mg/kg/d b.w.; *i.p.*)↓ in the levels of MDA and SOD in both areas of the brain (cerebral cortex and hippocampus).[@bib54]Noise stress-induced oxidative stress in brain (wistar Albino rats)(α)-asarone\
(9 mg/kg/d b.w.; *i.p.*)↓ in the levels of SOD and LPO content in hippocampus.\
↑ in the levels of CAT, GPx, GSH, Vitamin C and E in hippocampus.[@bib55]Dalton\'s ascites lymphoma induced tumor (swiss Albino mice)Methanolic extracts of *A. calamus* (100 and 200 mg/kg/d b.w.; *i.p.)*↑ in the liver antioxidant enzyme level of SOD, CAT, GPx, GSH, Vitamin C and E.\
↑ in the kidney antioxidant enzyme level of SOD, CAT, GPx, GSH, LPO and Vitamin E.\[[@bib42], [@bib43], [@bib44]\][^3]

2.4. Toxicity profile of *A. calamus* or asarone {#sec2.4}
------------------------------------------------

In acute toxicity studies, *A. calamus* and/or its bioactive phytochemicals asarone were found to be safe at lower doses as summarized in [Table 4](#tbl4){ref-type="table"}. An acute toxicity study of (α)-asarone (150, 200, 250, 300 and 350 mg/kg b.w.; *i.p.*) was undertaken by Morales *et al.* in male BALB/c mice for 14 days. The most frequent clinical signs observed among the animals were ptosis, ataxia, piloerection and dyspnea [@bib39]. In another study Liu *et al.* tested the effect of (β)-asarone (0.5, 0.75, 1, 1.25, 1.5, 1.75 and 2 g/kg b.w.; *i.v.*) on BALB/c mice to evaluate the preliminary toxicity. They reported that the animals that received (β)-asarone did not exhibit any behavior change within 24 h of treatment. Further they performed a long-term toxicity test for 90 days at the dosages of 10, 20 and 50 mg/kg/d. Results showed a dose-dependent toxicology with increase in number of white blood cells (WBC) and decrease in number of red blood cells (RBC) at 10 mg/kg. Additionally, the levels of serum K^+^ decreased at the dose of 20 mg/kg and Cl^−^ increased in 50 mg/kg treated mice [@bib28].Table 4Acute toxicity studies of *A. calamus* and/or its bioactive phytochemicals asarone (alpha (α)-and, beta (β)-asarone).Table 4Animal species/strain/genderMedian lethal dose (LD~50~)Reference(α)-asarone(β)-asaroneBALB/c mice (male)245.2 mg/kg b.w.; *i.p.*\--[@bib39]Rat\--1010 mg/kg b.w.; *p.o.*[@bib40]Mice\--184 mg/kg b.w.; *i.p.*[@bib40]Swiss mice (male)\>1000 mg/kg b.w.; *p.o.*\--[@bib56]BALB/c mice (both gender)\--1.56 g/kg b.w.; *i.v.*[@bib28][^4]

In sub-acute toxicity study, Sprague Dawley rats treated with (β)-asarone (100 mg/kg/d b.w.; *i.p.*) exhibited characteristic weight loss and decreased food consumption. Additionally, the weight of heart and thymus were reduced and weight of adrenals was increased. Furthermore, there was no significant changes in haematological and biochemical parameters indicating hepatotoxicity [@bib40]. In a two-year feeding study, Osborne-Mendel fed the male rats with a diet containing either (β)-asarone or calamus oil (400, 800 or 2000 mg/kg). The rats developed an increased incidence of leiomyosarcomas in small intestine. Microscopic analysis revealed cardiac atrophy, fat infiltration and fibrosis in heart of the animals. Further, rats fed with the Jammu oil of calamus (0, 50, 100 or 5000 mg/kg) for two years developed early mortality, liver and heart lesions at a dose of 5000 mg/kg [@bib40].

3. Conclusions {#sec3}
==============

Cancer is one of the growing health problems worldwide, posing a threat to human social and economic conditions. Regardless of the advanced treatment modality available for the treatment of cancer such as chemotherapy, surgical resection, radiotherapy and phototherapy, the survival rate has not been enhanced because of its high recurrence, toxic side-effects and metastasis rate. Hence, on-going efforts in search of anti-cancer agents derived from natural sources with low toxicity and greater enhancement of survival is gaining interest among many researchers. Based on the available literature, it appears that natural phytochemicals obtained from the plants, have been explored for their anti-cancer activity. *Acorus calamus*, commonly known as the 'sweet flag' has a rich history in the Indian and Chinese traditional medicine and found to be a popular remedy with great efficacy for various diseases. The information presented in this review focuses and summarizes the anti-cancer activity of *A*. *calamus* and/or its bioactive phytochemicals asarones (alpha (α)-and, beta (β)-asarone) including the underlying molecular mechanisms. Collectively, the mechanism underlying cancer chemo-prevention of *A*. *calamus* and/or its bioactive phytochemicals asarone includes variation of all kinds of cancer hallmarks. These includes regulation of cell proliferation and cell cycle arrest, induction of apoptosis, inhibition of angiogenesis as modulated via different signal transduction pathways. Still, extensive *in-vivo* studies are necessary using various models to understand the molecular mechanism behind the pharmacological activity of the bioactive phytochemicals derived from *A*. *calamus*. We believe that the evidence presented in this article could be a possible source for researchers to conduct future studies pertaining to *A*. *calamus* and/or its bioactive phytochemical asarone for cancer chemoprevention.
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[^1]: Abbreviations: hnRNP A2/B1: Heterogeneous nuclear ribonucleoproteins; TRAIL: TNF-related apoptosis-inducing ligand; FasL: Fas ligand; CCK-8: Cell counting kit 8; Oct-1, 4: Octamer-binding protein-1,4; TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling.

[^2]: Abbreviations: b.w.: body weight; d: day; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.

[^3]: Abbreviations: b.w.: body weight; d: day; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.

[^4]: Abbreviations: b.w.: body weight; p.o.: per oral route; i.v.: intravenous route i.p.: intraperitoneal route.
